Peter Schmid
MD, PhD
Professor and Lead, Breast Cancer Research
👥Biography 个人简介
Peter Schmid led the KEYNOTE-522 trial at Barts Cancer Institute which established pembrolizumab combined with chemotherapy as standard neoadjuvant and adjuvant therapy for early TNBC. His career has focused on biologically stratified treatment approaches for TNBC, including androgen receptor-targeting and novel immunotherapy combinations. He has contributed to understanding mechanisms of neoadjuvant immunotherapy response and resistance in early TNBC. He is a leading voice in early breast cancer clinical trial design and regulatory strategy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Peter Schmid 的研究动态
Follow Peter Schmid's research updates
留下邮箱，当我们发布与 Peter Schmid（Queen Mary University of London / Barts Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment